Clemastine Fumarate Syrup

Manufacturer
Lannett Company, Inc.
Effective date
2012-06-18
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
12
Source
legacy-cache
Hydrated at
2026-08-02 00:59:31

Label at a glance#

ProductClemastine Fumarate
Active ingredientCLEMASTINE FUMARATE
Label structure11 sections

Indications and uses

Clemastine Fumarate Syrup is indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and lacrimation. Clemastine Fumarate Syrup is indicated for use in pediatric populations (age 6 years through 12) and adults (see DOSAGE AND ADMINISTRATION). It should be noted that clemastine fumarate is indicated for the relief of mild uncomplicated allergic skin manifestatio...

Dosage and administration

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND RESPONSE OF THE PATIENT. Pediatric: Children aged 6 to 12 years: For Symptoms Of Allergic Rhinitis -The starting dose is 1 teaspoonful (0.5 mg clemastine) twice daily. Since single doses of up to 2.25 mg clemastine were well tolerated by this age group, dosage may be increased as required, but not to exceed 6 teaspoonfuls daily (3 mg clemastine). For Urtic...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Each teaspoonful (5 mL) of Clemastine Fumarate Syrup for oral administration contains clemastine 0.5 mg (present as clemastine fumarate 0.67 mg). Other ingredients: alcohol 5.5%, flavor, fumaric acid, methylparaben, propylene glycol, propylparaben, purified water, saccharin sodium, sorbitol in a buffered solution. Clemastine fumarate belongs to the benzhydryl ether group of antihistaminic compounds. The chemical name is (+)-(2R)-2-[2-[[(R)-p-Chloro-α-methyl-α-phenylbenzyl]- oxy]ethyl]-1-methylpyrrolidine fumarate and has the following structural formula:

structure of clemastine fumerate
structure of clemastine fumerate

C21H26CINO.C4H4O4                                          M.W. 459.97

CAS Registration Number 145976-57-9

Clemastine fumarate occurs as a colorless to faintly yellow, practically odorless, crystalline powder. Clemastine Fumarate Syrup has an approximate pH of 6.2.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Clemastine fumarate is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines competitively antagonize various physiological effects of histamine including increased capillary permeability and dilatation, the formation of edema, the "flare" and "itch" response, and gastrointestinal and respiratory smooth muscle constriction. Within the vascular tree, H1-receptor antagonists inhibit both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, H1- receptor antagonists can produce CNS stimulation or depression. Most antihistamines exhibit central and/or peripheral anticholinergic activity. Antihistamines act by competitively blocking H1-receptor sites. Antihistamines do not pharmacologically antagonize or chemically inactivate histamine, nor do they prevent the release of histamine.

PHARMACOKINETICS

PHARMACOKINETICS SECTION

Antihistamines are well-absorbed following oral administration. Chlorpheniramine maleate, clemastine fumarate, and diphenhydramine hydrochloride achieve peak blood levels within 2-5 hours following oral administration. The absorption of antihistamines is often partially delayed by the use of controlled release dosage forms. In these instances, plasma concentrations from identical doses of the immediate and controlled release dosage forms will not be similar. Tissue distribution of the antihistamines in humans has not been established.

Antihistamines appear to be metabolized in the liver chiefly via mono- and didemethylation and glucuronide conjugation. Antihistamine metabolites and small amounts of unchanged drug are excreted in the urine. Small amounts of the drugs may also be excreted in breast milk.

In normal human subjects who received histamine injections over a 24-hour period, the antihistaminic activity of clemastine fumarate reached a peak at 5-7 hours, persisted for 10-12 hours and, in some cases, for as long as 24 hours. Pharmacokinetic studies in man utilizing 3H and 14C labeled compound demonstrates that: clemastine fumarate is rapidly absorbed from the gastrointestinal tract, peak plasma concentrations are attained in 2-4 hours, and urinary excretion is the major mode of elimination.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Clemastine Fumarate Syrup is indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and lacrimation. Clemastine Fumarate Syrup is indicated for use in pediatric populations (age 6 years through 12) and adults (see DOSAGE AND ADMINISTRATION).

It should be noted that clemastine fumarate is indicated for the relief of mild uncomplicated allergic skin manifestations of urticaria and angioedema at the 2 mg dosage level only.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Antihistamines are contraindicated in patients hypersensitive to the drug or to other antihistamines of similar chemical structure (see PRECAUTIONS-Drug Interactions). Antihistamines should not be used in newborn or premature Infants. Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers (See PRECAUTIONS-Nursing Mothers).

WARNINGS

WARNINGS SECTION

Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, and bladder neck obstruction.

Use with CNS Depressants: Clemastine fumarate has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.)

Use in Activities Requiring Mental Alertness: Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.

Use in the Elderly (approximately 60 years or older): Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

PRECAUTIONS

PRECAUTIONS SECTION

General: Clemastine fumarate should be used with caution in patients with: history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, and hypertension. Information for Patients:

  • Patients taking antihistamines should receive the following information and instructions: Antihistamines are prescribed to reduce allergic symptoms.
  • Patients should be questioned regarding a history of glaucoma, peptic ulcer, urinary retention, or pregnancy before starting antihistamine therapy.
  • Patients should be told not to take alcohol, sleeping pills, sedatives, or tranquilizers while taking antihistamines.
  • Antihistamines may cause drowsiness, dizziness, dry mouth, blurred vision, weakness, nausea, headache, or nervousness in some patients.
  • Patients should avoid driving a car or working with hazardous machinery until they assess the effects of this medicine.
  • Patients should be told to store this medicine in a tightly closed container in a dry, cool place away from heat or direct sunlight and out of the reach of children.

Drug Interactions

DRUG INTERACTIONS SECTION

Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol. Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis and Mutagenesis: In a 2-year oral study in the rat at a dose of 84 mg/kg (about 500 times the adult human dose) and an 85-week oral study in the mouse at 206 mg/kg (about 1300 times the adult human dose), clemastine fumarate showed no evidence of carcinogenesis. No mutagenic studies have been conducted with clemastine fumarate.

Impairment of Fertility: Oral doses of clemastine fumarate in the rat produced a decrease in mating ability of the male at 312 times the adult human dose. This effect was not found at 156 times the adult human dose.

Pregnancy

PREGNANCY SECTION

Pregnancy Category B: Oral reproduction studies performed with clemastine fumarate in rats and rabbits at doses up to 312 and 188 times the adult human doses respectively, have revealed no evidence of teratogenic effects.

There are no adequate and well-controlled studies of Clemastine Fumarate Syrup in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Although quantitative determination of antihistaminic drugs in breast milk have not been reported, qualitative tests have documented the excretion of diphenhydramine, pyrilamine, and tripelennamine in human milk.

Because of the potential for adverse reactions in nursing infants from antihistamines, a decision should be made whether to discontinue nursing or to discontinue the drug.

Pediatric Use

PEDIATRIC USE SECTION

The safety and efficacy of Clemastine Fumarate Syrup has been confirmed in the pediatric population (age 6 years through 12). Safety and dose tolerance studies have confirmed children 6 through 11 years tolerated dosage ranges of 0.75 to 2.25 mg clemastine. In infants and children particularly, antihistamines in overdosage may produce hallucinations, convulsions, and death. Symptoms of antihistamine toxicity in children may include fixed dilated pupils, flushed face, dry mouth, fever, excitation, hallucinations, ataxia, incoordination, athetosis, tonic-clonic convulsions, and postictal depression (see OVERDOSAGE).

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions are underlined: Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.

Gastrointestinal System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.

Respiratory System: Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

Cardiovascular System: Hypotension, headache, palpitations, tachycardia, extrasystoles.

Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis.

Genitourinary System: Urinary frequency, difficult urination, urinary retention, early menses.

General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.

OVERDOSAGE

OVERDOSAGE SECTION

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. In children, stimulation predominates initially in a syndrome which may include excitement, hallucinations, ataxia, incoordination, muscle twitching, athetosis, hyperthermia, cyanosis convulsions, tremors, and hyperreflexia followed by postictal depression and cardio respiratory arrest. Convulsions in children may be preceded by mild depression. Dry mouth, fixed dilated pupils, flushing of the face, and fever are common. In adults, CNS depression, ranging from drowsiness to coma, is more common. The convulsant dose of antihistamines lies near the lethal dose. Convulsions indicate a poor prognosis.

In both children and adults, coma and cardiovascular collapse may occur.Deaths are reported especially in infants and children.

There is no specific therapy for acute overdosage with antihistamines. The latent period from ingestion to appearance of toxic effects is characteristically short (1/2-2 hours). General symptomatic and supportive measures should be instituted promptly and maintained for as long as necessary.

Since overdoses of other classes of drugs (i.e., tricyclic antidepressants) may also present anticholinergic symptomatology, appropriate toxicological analysis should be performed as soon as possible to identify the causative agent.

In the conscious patient, vomiting should be induced even though it may have occurred spontaneously. If vomiting cannot be induced, gastric lavage is indicated. Adequate precautions must be taken to protect against aspiration, especially in infants and children. Charcoal slurry or other suitable agents should be instilled into the stomach after vomiting or lavage. Saline cathartics or milk of magnesia may be of additional benefit.

In the unconscious patient, the airway should be secured with a cuffed endotracheal tube before attempting to evacuate the gastric contents. Intensive supportive and nursing care is indicated, as for any comatose patient.

If breathing is significantly impaired, maintenance of an adequate airway and mechanical support of respiration is the most effective means of providing adequate oxygenation. Hypotension is an early sign of impending cardiovascular collapse and should be treated vigorously. Although general supportive measures are important, specific treatment with intravenous infusion of a vasopressor titrated to maintain adequate blood pressure may be necessary.

Do not use with CNS stimulants.

Convulsions should be controlled by careful administration of diazepam or a short-acting barbiturate, repeated as necessary. Physostigmine may also be considered for use in controlling centrally mediated convulsions.

Ice packs and cooling sponge baths, not alcohol, can aid in reducing the fever commonly seen in children.

A more detailed review of antihistamine toxicology and overdose management is available in Gosselin, R.E., et al., "Clinical Toxicology of Commercial Products."

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND RESPONSE OF THE PATIENT.

Pediatric: Children aged 6 to 12 years:

For Symptoms Of Allergic Rhinitis -The starting dose is 1 teaspoonful (0.5 mg clemastine) twice daily. Since single doses of up to 2.25 mg clemastine were well tolerated by this age group, dosage may be increased as required, but not to exceed 6 teaspoonfuls daily (3 mg clemastine). For Urticaria and Angioedema -The starting dose is 2 teaspoonfuls (1 mg clemastine) twice daily, not to exceed 6 teaspoonfuls daily (3 mg clemastine).

Adults and Children 12 years and Over:

For Symptoms Of Allergic Rhinitis -The starting dose is 2 teaspoonfuls (1.0 mg clemastine) twice daily. Dosage may be increased as required, but not to exceed 12 teaspoonfuls daily (6 mg clemastine). For Urticaria and Angioedema -The starting dose is 4 teaspoonfuls (2 mg clemastine) twice daily, not to exceed 12 teaspoonfuls daily (6 mg clemastine).

HOW SUPPLIED

HOW SUPPLIED SECTION

Clemastine Fumarate Syrup: clemastine 0.5 mg/5 mL (present as clemastine fumarate 0.67 mg/5 mL) is as a clear, colorless liquid with a fruity flavor, and supplied as follows:

120 mL bottle(NDC 54838-514-40)

473 mL (1 Pint) bottle (NDC 54838-514-80)

Store below 25°C (77°F). Store in an upright position. Dispense in a tight, light-resistant container.

Manufactured by:
Silarx Pharmaceuticals, Inc.
Spring Valley, NY 10977

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


Container Label 120mL
Container Label 120mL

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54838-514-40ML - Milliliter54838-51416bada56-5809-4468-be6b-1798356fdfbb12012-07-24
54838-514-80ML - Milliliter54838-514ab2ae5e6-c4b0-40ef-ba1a-1eb3d6f2622f12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Clemastine FumarateACTIVE INGREDIENT19259EGQ3D9
ClemastineACTIVE MOIETY95QN29S1ID9
alcoholINACTIVE INGREDIENT3K9958V90M9
fumaric acidINACTIVE INGREDIENT88XHZ131319
methylparabenINACTIVE INGREDIENTA2I8C7HI9T9
propylene glycolINACTIVE INGREDIENT6DC9Q167V39
propylparabenINACTIVE INGREDIENTZ8IX2SC1OH9
saccharin sodium dihydrateINACTIVE INGREDIENTSB8ZUX40TY9
sorbitolINACTIVE INGREDIENT506T60A25R9
waterINACTIVE INGREDIENT059QF0KO0R9

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54838-51454838-514-40, 54838-514-80

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 7 · 372 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
sorbitolSORBITOL506T60A25RSOLUTION, CONCENTRATE / ORAL300 mg/1mlExact identifier — unii candidate
44 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSHAMPOO / TOPICAL0.15 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3INJECTION / INTRAVENOUS16624 mgExact identifier — unii candidate
81 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSUSPENSION / TOPICAL0.24 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
sorbitolSORBITOL506T60A25RCAPSULE / ORAL1111 mgExact identifier — unii candidate
44 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / TOPICAL4974 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / INTRAMUSCULAR4000 mgExact identifier — unii candidate
81 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYOINTMENT / DENTALNAExact identifier — unii candidate
34 equally ranked IID candidates
alcoholALCOHOL3K9958V90MLOTION / TOPICAL305 mgExact identifier — unii candidate
59 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3GEL / RECTAL3315 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SPRAY / NASAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
sorbitolSORBITOL506T60A25RCREAM / TOPICAL36.8 %w/wExact identifier — unii candidate
44 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3GEL, METERED / TOPICAL1225 mgExact identifier — unii candidate
81 equally ranked IID candidates
alcoholALCOHOL3K9958V90MJELLY / VAGINALNAExact identifier — unii candidate
59 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHSHAMPOO / TOPICAL0.03 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYOINTMENT / TOPICALNAExact identifier — unii candidate
34 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSOLUTION / NASAL250 mgExact identifier — unii candidate
79 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHOINTMENT / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
sorbitolSORBITOL506T60A25RTABLET / ORAL337.28 mgExact identifier — unii candidate
44 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / TOPICAL5.28 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
sorbitolSORBITOL506T60A25RPASTE / DENTAL14.6 %w/wExact identifier — unii candidate
44 equally ranked IID candidates
alcoholALCOHOL3K9958V90MMOUTHWASH / BUCCAL200 mg/1mlExact identifier — unii candidate
59 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TINJECTION / PERIDURAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TDROPS / AURICULAR (OTIC)0.01 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYTABLET, CHEWABLE / ORAL84 mgExact identifier — unii candidate
34 equally ranked IID candidates
alcoholALCOHOL3K9958V90MLIQUID / INTRAMUSCULAR400 mgExact identifier — unii candidate
59 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYPOWDER, FOR SUSPENSION / ORAL85 mgExact identifier — unii candidate
34 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3LOTION / TOPICAL3399 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR0.4 mgExact identifier — unii candidate
68 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3GEL / TRANSDERMAL500 mgExact identifier — unii candidate
81 equally ranked IID candidates
alcoholALCOHOL3K9958V90MSPRAY / NASAL20 mgExact identifier — unii candidate
59 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / RESPIRATORY (INHALATION)25 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3AEROSOL, METERED / RECTALNAExact identifier — unii candidate
81 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3SUSPENSION / RECTAL90400 mgExact identifier — unii candidate
81 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYPOWDER, FOR SOLUTION / ORAL199 mgExact identifier — unii candidate
34 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TTABLET, COATED / ORAL0.8 mgExact identifier — unii candidate
79 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHPASTE, DENTIFRICE / DENTALNAExact identifier — unii candidate
68 equally ranked IID candidates
alcoholALCOHOL3K9958V90MAEROSOL, SPRAY / RESPIRATORY (INHALATION)35.75 %w/wExact identifier — unii candidate
59 equally ranked IID candidates
sorbitolSORBITOL506T60A25RSUSPENSION / RECTAL46.18 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHINJECTION / SUBCUTANEOUS2 mgExact identifier — unii candidate
68 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYPASTE / DENTAL0.3 %w/wExact identifier — unii candidate
34 equally ranked IID candidates
alcoholALCOHOL3K9958V90MCONCENTRATE / BUCCAL679 mg/1mlExact identifier — unii candidate
59 equally ranked IID candidates
alcoholALCOHOL3K9958V90MINJECTION, SOLUTION / INTRAMUSCULAR1000 mgExact identifier — unii candidate
59 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYSUSPENSION / ORAL5000 mg/5mlExact identifier — unii candidate
34 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TSOLUTION/ DROPS / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
sorbitolSORBITOL506T60A25RSOLUTION / NASAL25 mg/1mlExact identifier — unii candidate
44 equally ranked IID candidates
sorbitolSORBITOL506T60A25RLOTION / TOPICAL10.7 %w/wExact identifier — unii candidate
44 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TINJECTION / INTRA-ARTICULAR0.24 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
saccharin sodium dihydrateSACCHARIN SODIUMSB8ZUX40TYSOLUTION / DENTAL0.05 %w/vExact identifier — unii candidate
34 equally ranked IID candidates
sorbitolSORBITOL506T60A25RINJECTION, SOLUTION / INTRAVENOUS4050 mgExact identifier — unii candidate
44 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CREAM, AUGMENTED / TOPICAL278 mgExact identifier — unii candidate
81 equally ranked IID candidates
sorbitolSORBITOL506T60A25RTABLET, CHEWABLE / ORAL3555 mgExact identifier — unii candidate
44 equally ranked IID candidates
alcoholALCOHOL3K9958V90MSOLUTION / INTRAVENOUS99 mgExact identifier — unii candidate
59 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHLIQUID / ORAL2 mgExact identifier — unii candidate
68 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3CAPSULE / ORAL1072 mgExact identifier — unii candidate
81 equally ranked IID candidates
propylparabenPROPYLPARABENZ8IX2SC1OHCAPSULE, EXTENDED RELEASE / ORAL0.22 mgExact identifier — unii candidate
68 equally ranked IID candidates
sorbitolSORBITOL506T60A25RINJECTION, SOLUTION / SUBCUTANEOUS4.7 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
sorbitolSORBITOL506T60A25RINJECTION / INTRASYNOVIAL45 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
propylene glycolPROPYLENE GLYCOL6DC9Q167V3FILM / BUCCAL1.48 mgExact identifier — unii candidate
81 equally ranked IID candidates
methylparabenMETHYLPARABENA2I8C7HI9TTABLET / ORAL1.8 mgExact identifier — unii candidate
79 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074884-001CLEMASTINE FUMARATECLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A074884-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17d4dbc9d85df4…
2026-10-15 13:18:302026-09A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17c2088c7a36db…
2026-09-14 22:38:342026-08A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-1784e616aacf4f…
2026-08-18 06:07:402026-07A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-1731067a03dcf5…
2025-08-23 18:47 UTC2025-08A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-176a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-1703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-172680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-175bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORALAA1997-12-17d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-1779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-171e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-178072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-175c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-175d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-174b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-1774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-1787673890dc5c…
2021-03-12 10:30 UTC2021-03A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-175aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-178869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-173f01610625f2…
2019-09-15 20:21 UTC2019-09A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17b00525d2431f…
2019-07-19 19:46 UTC2019-07A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-176a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-171c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-179b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-173f0d92c62455…
2023-05-13 08:27 UTC2023-05A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-17053a50430f4f…
2023-01-26 05:58 UTC2023-01A074884-001CLEMASTINE FUMARATEEQ 0.5MG BASE/5MLSYRUP / ORAL1997-12-173bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A074884-001AA1d4dbc9d85df4…
2026-10-15 13:18:302026-09A074884-001AA1c2088c7a36db…
2026-09-14 22:38:342026-08A074884-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A074884-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074884-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074884-001AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A074884-001AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074884-001AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074884-001AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074884-001AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074884-001AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074884-001AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074884-001AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074884-001AA1d06236e962d9…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A074884-001AA1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
02daafb3-13cf-4191-aa7c-1d36aef982323f5dbf44-7cad-491f-ad5f-ad4bd06682a62012-06-18Warnings, Adverse reactionsExact identifier
spl set id: 3f5dbf44-7cad-491f-ad5f-ad4bd06682a6

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.